All Title Author
Keywords Abstract

PLOS ONE  2012 

Differential Proteomics and Functional Research following Gene Therapy in a Mouse Model of Leber Congenital Amaurosis

DOI: 10.1371/journal.pone.0044855

Full-Text   Cite this paper   Add to My Lib


Leber congenital amaurosis (LCA) is one of the most severe forms of inherited retinal degeneration and can be caused by mutations in at least 15 different genes. To clarify the proteomic differences in LCA eyes, a cohort of retinal degeneration 12 (rd12) mice, an LCA2 model caused by a mutation in the RPE65 gene, were injected subretinally with an AAV vector (scAAV5-smCBA-hRPE65) in one eye, while the contralateral eye served as a control. Proteomics were compared between untreated rd12 and normal control retinas on P14 and P21, and among treated and untreated rd12 retinas and control retinas on P42. Gene therapy in rd12 mice restored retinal function in treated eyes, which was demonstrated by electroretinography (ERG). Proteomic analysis successfully identified 39 proteins expressed differently among the 3 groups. The expression of 3 proteins involved in regulation of apoptosis and neuroptotection (alpha A crystallin, heat shock protein 70 and peroxiredoxin 6) were investigated further. Immunofluorescence, Western blot and real-time PCR confirmed the quantitative changes in their expression. Furthermore, cell culture studies suggested that peroxiredoxin 6 could act in an antioxidant role in rd12 mice. Our findings support the feasibility of gene therapy in LCA2 patients and support a role for alpha A crystallin, heat shock protein 70 and peroxiredoxin 6 in the pathogenetic mechanisms involved in LCA2 disease process.


[1]  Koenekoop RK (2004) An overview of Leber congenital amaurosis: a model to understand human retinal development. Surv Ophthalmol 49: 379–398.
[2]  Stone EM (2007) Leber congenital amaurosis – a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol 144: 791–811.
[3]  Wang P, Guo X, Zhang Q (2007) Further evidence of autosomal-dominant Leber congenital amaurosis caused by heterozygous CRX mutation. Graefes Arch Clin Exp Ophthalmol 245: 1401–1402.
[4]  Tzekov RT, Liu Y, Sohocki MM, Zack DJ, Daiger SP, et al. (2001) Autosomal dominant retinal degeneration and bone loss in patients with a 12-bp deletion in the CRX gene. Invest Ophthalmol Vis Sci 42: 1319–1327.
[5]  Pelletier V, Jambou M, Delphin N, Zinovieva E, Stum M, et al. (2007) Comprehensive survey of mutations in RP2 and RPGR in patients affected with distinct retinal dystrophies: genotype-phenotype correlations and impact on genetic counseling. Hum Mutat 28: 81–91.
[6]  Morimura H, Fishman GA, Grover SA, Fulton AB, Berson EL, et al. (1998) Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. Proc Natl Acad Sci U S A 95: 3088–3093.
[7]  Hamel CP, Tsilou E, Pfeffer BA, Hooks JJ, Detrick B, et al. (1993) Molecular cloning and expression of RPE65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro. J Biol Chem 268: 15751–15757.
[8]  Moiseyev G, Chen Y, Takahashi Y, Wu BX, Ma JX (2005) RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A 102: 12413–12418.
[9]  Woodruff ML, Wang Z, Chung HY, Redmond TM, Fain GL, et al. (2003) Spontaneous activity of opsin apoprotein is a cause of Leber congenital amaurosis. Nat Genet 35: 158–164.
[10]  Znoiko SL, Rohrer B, Lu K, Lohr HR, Crouch RK, et al. (2005) Downregulation of cone-specific gene expression and degeneration of cone photoreceptors in the Rpe65?/? mouse at early ages. Invest Ophthalmol Vis Sci 46: 1473–1479.
[11]  den Hollander AI, Roepman R, Koenekoop RK, Cremers FP (2008) Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 27: 391–419.
[12]  Pang JJ, Chang B, Kumar A, Nusinowitz S, Noorwez SM, et al. (2006) Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther 13: 565–572.
[13]  Dejneka NS, Surace EM, Aleman TS, Cideciyan AV, Lyubarsky A, et al. (2004) In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther 9: 182–188.
[14]  Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, et al. (2001) Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28: 92–95.
[15]  Narfstrom K, Bragadottir R, Redmond TM, Rakoczy PE, van Veen T, et al. (2003) Functional and structural evaluation after AAV. RPE65 gene transfer in the canine model of Leber's congenital amaurosis. Adv Exp Med Biol 533: 423–430.
[16]  Bennicelli J, Wright JF, Komaromy A, Jacobs JB, Hauck B, et al. (2008) Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 16: 458–465.
[17]  Le Meur G, Stieger K, Smith AJ, Weber M, Deschamps JY, et al. (2007) Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 14: 292–303.
[18]  Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, et al. (2005) Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12: 1072–1082.
[19]  Narfstrom K, Katz ML, Ford M, Redmond TM, Rakoczy E, et al. (2003) In vivo gene therapy in young and adult RPE65?/? dogs produces long-term visual improvement. J Hered 94: 31–37.
[20]  Jacobson SG, Boye SL, Aleman TS, Conlon TJ, Zeiss CJ, et al. (2006) Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther 17: 845–858.
[21]  Buch PK, Bainbridge JW, Ali RR (2008) AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther 15: 849–857.
[22]  Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231–2239.
[23]  Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240–2248.
[24]  Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, et al. (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979–990.
[25]  Simonelli F, Ziviello C, Testa F, Rossi S, Fazzi E, et al. (2007) Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients. Invest Ophthalmol Vis Sci 48: 4284–4290.
[26]  Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, et al. (2012) Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130: 9–24.
[27]  Lai CM, Yu MJ, Brankov M, Barnett NL, Zhou X, et al. (2004) Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65?/? knockout mouse eye results in limited rescue. Genet Vaccines Ther 2: 3.
[28]  Pawlyk BS, Smith AJ, Buch PK, Adamian M, Hong DH, et al. (2005) Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. Invest Ophthalmol Vis Sci 46: 3039–3045.
[29]  Kostic C, Crippa SV, Pignat V, Bemelmans AP, Samardzija M, et al. (2011) Gene therapy regenerates protein expression in cone photoreceptors in Rpe65(R91W/R91W) mice. PLoS One 6: e16588.
[30]  Li W, Kong F, Li X, Dai X, Liu X, et al. (2009) Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye. Mol Vis 15: 267–275.
[31]  Tezel G, Yang X, Cai J (2005) Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest Ophthalmol Vis Sci 46: 3177–3187.
[32]  Li X, Li W, Dai X, Kong F, Zheng Q, et al. (2011) Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis. Invest Ophthalmol Vis Sci 52: 7–15.
[33]  Pang J, Boye SE, Lei B, Boye SL, Everhart D, et al. (2010) Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Ther 17: 815–826.
[34]  Cavusoglu N, Thierse D, Mohand-Said S, Chalmel F, Poch O, et al. (2003) Differential proteomic analysis of the mouse retina: the induction of crystallin proteins by retinal degeneration in the rd1 mouse. Mol Cell Proteomics 2: 494–505.
[35]  Finnegan S, Robson J, Hocking PM, Ali M, Inglehearn CF, et al. (2010) Proteomic profiling of the retinal dysplasia and degeneration chick retina. Mol Vis 16: 7–17.
[36]  Augusteyn RC (2004) alpha-crystallin: a review of its structure and function. Clin Exp Optom 87: 356–366.
[37]  Fort PE, Lampi KJ (2011) New focus on alpha-crystallins in retinal neurodegenerative diseases. Exp Eye Res 92: 98–103.
[38]  Bernstein SL, Liu AM, Hansen BC, Somiari RI (2000) Heat shock cognate-70 gene expression declines during normal aging of the primate retina. Invest Ophthalmol Vis Sci 41: 2857–2862.
[39]  Bailey TA, Kanuga N, Romero IA, Greenwood J, Luthert PJ, et al. (2004) Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 45: 675–684.
[40]  Hidalgo-de-Quintana J, Evans RJ, Cheetham ME, van der Spuy J (2008) The Leber congenital amaurosis protein AIPL1 functions as part of a chaperone heterocomplex. Invest Ophthalmol Vis Sci 49: 2878–2887.
[41]  Siu AW, Lau MK, Cheng JS, Chow CK, Tam WC, et al. (2008) Glutamate-induced retinal lipid and protein damage: the protective effects of catechin. Neurosci Lett 432: 193–197.
[42]  Fatma N, Kubo E, Sen M, Agarwal N, Thoreson WB, et al. (2008) Peroxiredoxin 6 delivery attenuates TNF-alpha-and glutamate-induced retinal ganglion cell death by limiting ROS levels and maintaining Ca2+ homeostasis. Brain Res 1233: 63–78.
[43]  Tulsawani R, Kelly LS, Fatma N, Chhunchha B, Kubo E, et al. (2010) Neuroprotective effect of peroxiredoxin 6 against hypoxia-induced retinal ganglion cell damage. BMC Neurosci 11: 125.
[44]  Hejtmancik JF (1998) The genetics of cataract: our vision becomes clearer. Am J Hum Genet 62: 520–525.
[45]  Deretic D, Aebersold RH, Morrison HD, Papermaster DS (1994) Alpha A- and alpha B-crystallin in the retina. Association with the post-Golgi compartment of frog retinal photoreceptors. J Biol Chem 269: 16853–16861.
[46]  Vazquez-Chona F, Song BK, Geisert EE Jr (2004) Temporal changes in gene expression after injury in the rat retina. Invest Ophthalmol Vis Sci 45: 2737–2746.
[47]  Sakaguchi H, Miyagi M, Darrow RM, Crabb JS, Hollyfield JG, et al. (2003) Intense light exposure changes the crystallin content in retina. Exp Eye Res 76: 131–133.
[48]  Barbe MF, Tytell M, Gower DJ, Welch WJ (1988) Hyperthermia protects against light damage in the rat retina. Science 241: 1817–1820.
[49]  Beckmann RP, Mizzen LE, Welch WJ (1990) Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assembly. Science 248: 850–854.
[50]  Evans CG, Chang L, Gestwicki JE (2010) Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem 53: 4585–4602.
[51]  Whitlock NA, Lindsey K, Agarwal N, Crosson CE, Ma JX (2005) Heat shock protein 27 delays Ca2+-induced cell death in a caspase-dependent and -independent manner in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 46: 1085–1091.
[52]  Rhee SG, Kang SW, Chang TS, Jeong W, Kim K (2001) Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52: 35–41.
[53]  Chang TS, Jeong W, Choi SY, Yu S, Kang SW, et al. (2002) Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation. J Biol Chem 277: 25370–25376.
[54]  Kubo E, Singh DP, Fatma N, Akagi Y (2009) TAT-mediated peroxiredoxin 5 and 6 protein transduction protects against high-glucose-induced cytotoxicity in retinal pericytes. Life Sci 84: 857–864.
[55]  De La Paz MA, Zhang J, Fridovich I (1996) Antioxidant enzymes of the human retina: effect of age on enzyme activity of macula and periphery. Curr Eye Res 15: 273–278.
[56]  Maier CM, Chan PH (2002) Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neuroscientist 8: 323–334.
[57]  Organisciak DT, Darrow RM, Barsalou L, Darrow RA, Kutty RK, et al. (1998) Light history and age-related changes in retinal light damage. Invest Ophthalmol Vis Sci 39: 1107–1116.


comments powered by Disqus